 |
32 Diseases |  |
0 Trials |
|
0 Trials |  |
9 News |  |
- ||||| Venoglobulin-IH (polyethylene glycol treated human immunoglobulin G) / Mitsubishi Tanabe
Trial completion: A Study of the Efficacy and Safety of GB-0998 in Patients With Unexplained Recurrent Miscarriage (clinicaltrials.gov) - Nov 9, 2021
P3, N=99, Completed, Sponsor: Japan Blood Products Organization
Recruiting --> Completed
- | Venoglobulin-IH (polyethylene glycol treated human immunoglobulin G) / Mitsubishi Tanabe
Trial completion date, Trial primary completion date: A Study of the Efficacy and Safety of GB-0998 in Patients With Unexplained Recurrent Miscarriage (clinicaltrials.gov) - Aug 13, 2018
P3, N=80, Recruiting, Sponsor: Japan Blood Products Organization
Recruiting --> Completed Trial completion date: Jun 2019 --> Jun 2021 | Trial primary completion date: Feb 2019 --> Jan 2021
- |||| Venoglobulin-IH (polyethylene glycol treated human immunoglobulin G) / Mitsubishi Tanabe
Trial primary completion date: A Study of the Efficacy and Safety of GB-0998 in Patients With Unexplained Recurrent Miscarriage (clinicaltrials.gov) - Mar 8, 2017
P3, N=80, Recruiting, Sponsor: Japan Blood Products Organization
Trial completion date: Jun 2019 --> Jun 2021 | Trial primary completion date: Feb 2019 --> Jan 2021 Trial primary completion date: Feb 2017 --> Feb 2019
- || Venoglobulin-IH (polyethylene glycol treated human immunoglobulin G) / Mitsubishi Tanabe
Trial completion: The Desensitization Therapy With GB-0998 for Anti-donor Antibody-positive Recipients. (clinicaltrials.gov) - Feb 6, 2016
P2/3, N=17, Completed, Sponsor: Japan Blood Products Organization
Trial primary completion date: Feb 2017 --> Feb 2019 Recruiting --> Completed
- || Venoglobulin-IH (polyethylene glycol treated human immunoglobulin G) / Mitsubishi Tanabe
Trial completion: Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome (clinicaltrials.gov) - Feb 4, 2016
P3, N=21, Completed, Sponsor: Japan Blood Products Organization
Recruiting --> Completed Recruiting --> Completed
- ||| Venoglobulin-IH (polyethylene glycol treated human immunoglobulin G) / Mitsubishi Tanabe
New P3 trial: Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome (clinicaltrials.gov) - Jan 20, 2015
P3, N=25, Recruiting, Sponsor: Japan Blood Products Organization
- |||||||||| Venoglobulin-IH (polyethylene glycol treated human immunoglobulin G) / Mitsubishi Tanabe
New P3 trial: A Study of the Efficacy and Safety of GB-0998 in Patients With Unexplained Recurrent Miscarriage (clinicaltrials.gov) - Jul 10, 2014
P3, N=80, Recruiting, Sponsor: Japan Blood Products Organization
- ||| Venoglobulin-IH (polyethylene glycol treated human immunoglobulin G) / Mitsubishi Tanabe
New P2/3 trial: The Desensitization Therapy With GB-0998 for Anti-donor Antibody-positive Recipients. (clinicaltrials.gov) - Jan 7, 2014
P2/3, N=15, Recruiting, Sponsor: Japan Blood Products Organization
- | Venoglobulin-IH (polyethylene glycol treated human immunoglobulin G) / Mitsubishi Tanabe
Enrollment change: Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM) (clinicaltrials.gov) - Feb 20, 2012
P3, N=26, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
Recruiting --> Completed N=20 --> 26